https://seekingalpha.com/article/4764992-aldeyra-therapeutics-is-severely-undervalued-before-pdufa [Seeking Alpha]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Seeking Alpha
Despite a controversial deal with AbbVie, Aldeyra remains financially solid, with $100M in cash and potential milestone payments. The DED market is strong, and reproxalap's data surpasses competitors, indicating significant undervaluation of Aldeyra's stock. With a market cap of $368M and promising assets, Aldeyra presents a compelling investment opportunity in the biotech sector. Richard Drury My last Aldeyra ( NASDAQ: ALDX article from September 2023 didn't age well because, despite my positive coverage, ALDX stock crashed within a month on the news that the FDA would not approve reproxalap's NDA for dry eye disease in its About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app an
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Psoriasis Treatment Market Size to Hit USD 54.40 Billion by 2032 Driven by Advances in Biologic and Innovative Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Why AbbVie (ABBV) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- 3 ETFs to Buy Now for Passive Dividend Income [Yahoo! Finance]Yahoo! Finance
- Cosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch Health, Johnson & Johnson, Apyx Medical, Hologic, Merz Pharma, Galderma, Cynosure [Yahoo! Finance]Yahoo! Finance
- Cosmetic Surgery and Procedure Market Size is Projected to Reach USD 419.97 Billion by 2033, Growing at a CAGR of 14.70%: Straits Research [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 1/31/25 - Beat
ABBV
Sec Filings
- 3/14/25 - Form 144
- 3/10/25 - Form PRE
- 3/10/25 - Form 3
- ABBV's page on the SEC website